CHAD CREIGHTON to Drug Resistance, Neoplasm
This is a "connection" page, showing publications CHAD CREIGHTON has written about Drug Resistance, Neoplasm.
Connection Strength
1.111
-
Widespread molecular patterns associated with drug sensitivity in breast cancer cell lines, with implications for human tumors. PLoS One. 2013; 8(12):e71158.
Score: 0.298
-
A gene transcription signature associated with hormone independence in a subset of both breast and prostate cancers. BMC Genomics. 2007 Jun 28; 8:199.
Score: 0.190
-
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81.
Score: 0.087
-
Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer. Cell Death Dis. 2015 Mar 19; 6:e1699.
Score: 0.081
-
An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul; 24(7):809-19.
Score: 0.077
-
Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance. Neoplasia. 2014 May; 16(5):390-402.
Score: 0.076
-
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Res Treat. 2012 Jul; 134(2):583-93.
Score: 0.067
-
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 2008 Sep 15; 68(18):7493-501.
Score: 0.052
-
YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer. Oncogene. 2021 04; 40(13):2407-2421.
Score: 0.031
-
In vivo?modeling of metastatic human high-grade serous ovarian cancer in mice. PLoS Genet. 2020 06; 16(6):e1008808.
Score: 0.029
-
GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat. 2018 Jul; 170(2):279-292.
Score: 0.025
-
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6600-E6609.
Score: 0.023
-
A genetic cell context-dependent role for ZEB1 in lung cancer. Nat Commun. 2016 07 26; 7:12231.
Score: 0.022
-
HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes. Cancer Res. 2016 Mar 15; 76(6):1463-75.
Score: 0.022
-
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
Score: 0.020
-
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008 Feb 01; 68(3):826-33.
Score: 0.012